Niagen Bioscience, Inc. (NAGE)
Nasdaq · Consumer Defensive · Packaged Foods
$2.68−3.94%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $212M
- P/E (trailing)
- 14.9
- Forward P/E
- 26.8
- 52-week range
- $2.61 – $7.95
- 52-week change
- −61.14%
- EPS (trailing)
- $0.18
- Analyst rating
- 1.0 Strong buy
- Next earnings
- Nov 3, 2026
Fiscal year to Dec 2025
- Revenue
- $129M (+29.94%)
- Net income
- $17.4M
- Operating margin
- 12.6%
- Diluted EPS
- $0.20
From the company’s annual report on SEC EDGAR.
About Niagen Bioscience, Inc.
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceutical-grade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and authorized healthcare practitioners resellers. The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025. Niagen Bioscience, Inc.
Headquarters: Los Angeles, United States · 117 employees · niagenbioscience.com